Total submissions: 5
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Counsyl | RCV000169332 | SCV000220673 | likely pathogenic | Primary hyperoxaluria, type I | 2014-09-05 | criteria provided, single submitter | literature only | |
| Invitae | RCV001054309 | SCV001218618 | pathogenic | not provided | 2024-01-13 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 36 of the AGXT protein (p.Arg36Cys). This variant is present in population databases (rs180177157, gnomAD 0.006%). This missense change has been observed in individuals with primary hyperoxaluria (PMID: 15356974, 24988064). ClinVar contains an entry for this variant (Variation ID: 188957). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt AGXT protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects AGXT function (PMID: 17495019, 22923379, 24718375). For these reasons, this variant has been classified as Pathogenic. |
| Fulgent Genetics, |
RCV000169332 | SCV002809818 | pathogenic | Primary hyperoxaluria, type I | 2022-02-15 | criteria provided, single submitter | clinical testing | |
| Baylor Genetics | RCV000169332 | SCV004194872 | pathogenic | Primary hyperoxaluria, type I | 2024-03-23 | criteria provided, single submitter | clinical testing | |
| Clinical Biochemistry Laboratory, |
RCV000169332 | SCV000239603 | pathogenic | Primary hyperoxaluria, type I | 2014-11-27 | no assertion criteria provided | in vitro |